{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T22:57:48Z","timestamp":1776725868369,"version":"3.51.2"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Oral corticosteroids (OCS) are used for maintenance treatment of myasthenia gravis (MG). Prolonged use of higher-dose OCS may provoke serious adverse events. Therefore, Japanese clinical guidelines recommend an OCS dose target of \u22645\u202fmg\/day. This retrospective study aimed to compare the burden of MG between patients achieving this target and non-achievers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data were obtained from three Japanese healthcare databases (JMDC, NHI and LSEHS) between 2014 and 2021. Patients with MG starting immunotherapy were enrolled and data were collected over 2\u202fyears following start of immunotherapy. Exposure to OCS was determined from medication delivery records; achievers and non-achievers of the \u22645\u202fmg\/day target during follow-up were identified. Outcomes evaluated were confirmed incident diabetes, new osteoporotic fracture, and total and MG-related costs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Overall, 459 patients were analyzed. Of these, 94 patients (58.4%) in the JMDC population, 96 (64.0%) in the NHI population and 119 (80.4%) in the LSEHS population achieved the \u22645\u202fmg\/day target. Incident confirmed diabetes in the JMDC population and new osteoporotic fractures in the LSEHS population were less frequent in target achievers than in non-achievers (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.01 and\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.05, respectively). In target achievers in the JMDC and LSEHS populations, total and MG-related costs were lower (both\n                      <jats:italic>p<\/jats:italic>\n                      \u202f\u2264\u202f0.01) than in non-achievers.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>OCS dose target non-achievers carry a higher burden than achievers. Broader implementation of effective treatment strategies is required to reduce long-term use of higher-dose OCS and the associated burden.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2025.1662173","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T15:20:07Z","timestamp":1761146407000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Disease burden of myasthenia gravis in relation to oral corticosteroid dose: an insurance claims database study in Japan"],"prefix":"10.3389","volume":"16","author":[{"given":"Makoto","family":"Samukawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shingo","family":"Konno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiyuki","family":"Uzawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Taki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Todaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Izumi","family":"Mishiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9line","family":"Quelen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zuzanna","family":"\u0141ukowicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renata","family":"Majewska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yohei","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,22]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.molimm.2022.08.018","article-title":"Complement and myasthenia gravis","volume":"151","author":"Sanderson","year":"2022","journal-title":"Mol Immunol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1002\/mus.23445","article-title":"Myasthenic crisis patients who require intensive care unit management","volume":"46","author":"Sakaguchi","year":"2012","journal-title":"Muscle Nerve"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","article-title":"International consensus guidance for Management of Myasthenia Gravis: 2020 update","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.3390\/jcm10112235","article-title":"Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations","volume":"10","author":"Dresser","year":"2021","journal-title":"J Clin Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"e0126579","DOI":"10.1371\/journal.pone.0126579","article-title":"Association between glucocorticoid-induced osteoporosis and myasthenia gravis: a cross-sectional study","volume":"10","author":"Konno","year":"2015","journal-title":"PLoS One"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.3390\/healthcare12171793","article-title":"Long-term bone density changes and fracture risk in myasthenia gravis: implications for FRAX(\u00ae) tool application","volume":"12","author":"Konno","year":"2024","journal-title":"Healthcare (Basel)"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/mus.24213","article-title":"Health-related quality-of-life and treatment targets in myasthenia gravis","volume":"50","author":"Utsugisawa","year":"2014","journal-title":"Muscle Nerve"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/mus.23398","article-title":"The MG-QOL15 Japanese version: validation and associations with clinical factors","volume":"46","author":"Masuda","year":"2012","journal-title":"Muscle Nerve"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"e000313","DOI":"10.1136\/bmjopen-2011-000313","article-title":"Factors associated with depressive state in patients with myasthenia gravis: a multicentre cross-sectional study","volume":"1","author":"Suzuki","year":"2011","journal-title":"BMJ Open"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"e933296","DOI":"10.12659\/MSM.933296","article-title":"Adverse side effects associated with corticosteroid therapy: a study in 39 patients with generalized myasthenia gravis","volume":"27","author":"Johnson","year":"2021","journal-title":"Med Sci Monit"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/s41574-022-00683-6","article-title":"Fresh insights into glucocorticoid-induced diabetes mellitus and new therapeutic directions","volume":"18","author":"Li","year":"2022","journal-title":"Nat Rev Endocrinol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s00198-021-06101-3","article-title":"The use of oral glucocorticoids and the risk of major osteoporotic fracture in patients with myasthenia gravis","volume":"33","author":"Safipour","year":"2022","journal-title":"Osteoporos Int"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/cen3.12739","article-title":"The Japanese clinical guidelines 2022 for myasthenia gravis and Lambert\u2013Eaton myasthenic syndrome","volume":"14","author":"Murai","year":"2023","journal-title":"Clin Exp Neuroimmunol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/cen3.12180","article-title":"Japanese clinical guidelines for myasthenia gravis: putting into practice","volume":"6","author":"Murai","year":"2015","journal-title":"Clin Exp Neuroimmunol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards. Task force of the medical scientific advisory Board of the Myasthenia Gravis Foundation of America","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/nyas.13544","article-title":"Rationale for the clinical guidelines for myasthenia gravis in Japan","volume":"1413","author":"Murai","year":"2018","journal-title":"Ann N Y Acad Sci"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1136\/jnnp-2022-330519","article-title":"Effectiveness of early cycles of fast-acting treatment in generalised myasthenia gravis","volume":"94","author":"Uzawa","year":"2023","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s00415-025-13113-0","article-title":"Changes in corticosteroid and non-steroidal immunosuppressive therapy with long-term zilucoplan treatment in generalized myasthenia gravis","volume":"272","author":"Hewamadduma","year":"2025","journal-title":"J Neurol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"6209","DOI":"10.1007\/s00415-024-12588-7","article-title":"A real-life experience with eculizumab and efgartigimod in generalized myasthenia gravis patients","volume":"271","author":"Pane","year":"2024","journal-title":"J Neurol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"e095496","DOI":"10.1136\/bmjopen-2024-095496","article-title":"Impact of 2014 Japanese practice guidelines on treatment patterns in patients with myasthenia gravis: an insurance claims database study","volume":"15","author":"Konno","year":"2025","journal-title":"BMJ Open"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"e5680","DOI":"10.1002\/pds.5680","article-title":"Inventory of real-world data sources in Japan: annual survey conducted by the Japanese Society for Pharmacoepidemiology Task Force","volume":"33","author":"Kumamaru","year":"2024","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1592\/phco.27.11.1512","article-title":"Diagnosis and treatment of adrenal insufficiency in the critically ill patient","volume":"27","author":"Asare","year":"2007","journal-title":"Pharmacotherapy"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/jdi.13641","article-title":"Appropriate definition of diabetes using an administrative database: a cross-sectional cohort validation study","volume":"13","author":"Nishioka","year":"2022","journal-title":"J Diabetes Investig"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1007\/s00198-022-06472-1","article-title":"Real-world evaluation of osteoporotic fractures using the Japan medical data vision database","volume":"33","author":"Fujiwara","year":"2022","journal-title":"Osteoporos Int"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.4236\/health.2021.1312102","article-title":"Estimation of diabetes prevalence, and evaluation of factors affecting blood glucose levels and use of medications in Japan","volume":"13","author":"Nawata","year":"2021","journal-title":"Health Qual Life Outcomes"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s00198-007-0543-5","article-title":"FRAX and the assessment of fracture probability in men and women from the UK","volume":"19","author":"Kanis","year":"2008","journal-title":"Osteoporos Int"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1007\/s00198-020-05294-3","article-title":"Determinants of imminent fracture risk in postmenopausal women with osteoporosis","volume":"31","author":"Barron","year":"2020","journal-title":"Osteoporos Int"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"3481","DOI":"10.1007\/s10072-024-07368-0","article-title":"Comorbidity in myasthenia gravis: multicentric, hospital-based, and controlled study of 178 Italian patients","volume":"45","author":"Di Stefano","year":"2024","journal-title":"Neurol Sci"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.2147\/TCRM.S138000","article-title":"A comprehensive overview on osteoporosis and its risk factors","volume":"14","author":"Pouresmaeili","year":"2018","journal-title":"Ther Clin Risk Manag"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.2147\/COPD.S433326","article-title":"A long-term study of adverse outcomes associated with Oral corticosteroid use in COPD","volume":"18","author":"Tse","year":"2023","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"193","DOI":"10.2147\/JAA.S176026","article-title":"Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study","volume":"11","author":"Price","year":"2018","journal-title":"J Asthma Allergy"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1136\/thorax-2022-219642","article-title":"Observational UK cohort study to describe intermittent oral corticosteroid prescribing patterns and their association with adverse outcomes in asthma","volume":"78","author":"Heatley","year":"2023","journal-title":"Thorax"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1080\/17446651.2020.1772051","article-title":"Updates in epidemiology, pathophysiology and management strategies of glucocorticoid-induced osteoporosis","volume":"15","author":"Chiodini","year":"2020","journal-title":"Expert Rev Endocrinol Metab"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1007\/s00198-024-07097-2","article-title":"The association between myasthenia gravis and risk of fracture: a systematic review and meta-analysis","volume":"35","author":"Lin","year":"2024","journal-title":"Osteoporos Int"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"625","DOI":"10.3233\/JND-200612","article-title":"Fracture risk in patients with myasthenia gravis: a population-based cohort study","volume":"8","author":"Kassardjian","year":"2021","journal-title":"J Neuromuscul Dis"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s00198-012-1970-5","article-title":"Fracture rate in patients with myasthenia gravis: the general practice research database","volume":"24","author":"Pouwels","year":"2013","journal-title":"Osteoporos Int"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1212\/WNL.0000000000000804","article-title":"Increased risk of osteoporosis in patients with myasthenia gravis: a population-based cohort study","volume":"83","author":"Yeh","year":"2014","journal-title":"Neurology"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"104956","DOI":"10.1016\/j.cellimm.2025.104956","article-title":"The real-world impact of corticosteroid-associated adverse events in myasthenia gravis: a patient-reported survey analysis","author":"Yan","year":"2025","journal-title":"Cell Immunol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/cen3.12731","article-title":"Japan MG registry: chronological surveys over 10\u202fyears","volume":"14","author":"Suzuki","year":"2023","journal-title":"Clin Exp Neuroimmunol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1080\/14712598.2023.2184257","article-title":"Biological therapies for myasthenia gravis","volume":"23","author":"Uzawa","year":"2023","journal-title":"Expert Opin Biol Ther"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1662173\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T15:20:08Z","timestamp":1761146408000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1662173\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,22]]},"references-count":43,"alternative-id":["10.3389\/fneur.2025.1662173"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2025.1662173","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,22]]},"article-number":"1662173"}}